<DOC>
	<DOCNO>NCT02551536</DOCNO>
	<brief_summary>Objectives : Allergic Rhinitis ( AR ) global health problem . 10-25 % population worldwide affect AR . Oral/intranasal H1-antihistamine , decongestant , leukotriene receptor antagonist , intranasal corticosteroid pillar management AR.Materials method : Seventy patient allergic rhinitis participate prospective , randomize , double-blind , parallel , active control , comparative 4 week trial . The patient age group 18-65 year either gender moderate-severe intermittent mild persistent allergic rhinitis include . The study inclusion criterion require subject Total Nasal Symptom Score ( TNSS ) 5 high . The patient randomly divide two treatment group montelukast-levocetrizine ( 10 mg 5 mg ) one group montelukast-fexofenadine ( 10 mg 120 mg ) another group . TNSS parameter main effectiveness parameter .</brief_summary>
	<brief_title>Montelukast Fexofenadine Versus Montelukast Levocetrizine Combination Allergic Rhinitis</brief_title>
	<detailed_description>Allergic Rhinitis ( AR ) global health problem . It cause major illness disability worldwide . Estimates indicate 10-25 % population worldwide affect AR . The main symptom AR include nasal congestion , rhinorrhea , itching , sneeze non-nasal symptom like burning , itch watery eye itch ear palate . These symptom considerable toll patient 's quality life interfere cognitive emotional functioning . The estimate annual cost attributable AR United States range $ 1.4 billion nearly $ 6 billion direct cost annually . Today 's antiallergic therapy base avoidance causative allergen , symptomatic pharmacotherapy , specific immunotherapy education . Oral/intranasal H1-antihistaminics , decongestant , leukotrienes receptor antagonist , intranasal corticosteroid pillar management allergic rhinitis . Second generation antihistamines become increasingly popular comparable efficacy low incidence adverse effect relative first generation counterpart . Levocetirizine , potent second generation histamine ( H1 ) receptor antagonist , effective persistent allergic rhinitis thus improves quality life reduces co-morbidities societal cost . Fexofenadine , selective , non sedating , second generation H1 receptor antagonist additional impact inflammatory mediator . Monteleukast highly selective type I receptor antagonist leukotriene D4 . The leukotrienes modifier anti-inflammatory bronchodilator property . The literature search establish addition antihistamine montelukast add benefit . The combination therapy montelukast antihistamine provide enhance complimentary effect thereby reduce symptom effectively . The result concomitant levocetirizine montelukast treatment well compare monotherapy levocetirizine symptom quality life allergic rhinitis . Fexofenadine along montelukast effective antihistaminic alone control allergic rhinitis symptom . There literature available comparison concomitant levocetirizine montelukast monotherapy placebo comparison concomitant fexofenadine montelukast monotherapy placebo . But scanty data available regard comparison concomitant montelukast-levocetirizine montelukast-fexofenadine .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>either gender moderatesevere intermittent mild persistent allergic rhinitis accord original Aria classification . subject Total Nasal Symptom Score ( TNSS ) 5 high . treat antihistaminics previous week . Patients willing sign write informed consent free clinically significant disease normal E.C.G participation child , pregnant female , nurse mother , patient asthma require chronic use inhale systemic corticosteroid history failure improve symptom antihistaminic drug treatment past 4.history allergy study medication tolerance antihistamine , 5.use study drug last 7 day . 6. subject significant hematopoietic , cardiovascular , hepatic , renal , neurologic , psychiatric autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>montelukast</keyword>
	<keyword>fexofenadine</keyword>
	<keyword>levocetrizine</keyword>
</DOC>